Accession Number:

ADA415846

Title:

Prostatic Fluid Cells

Descriptive Note:

Annual rept. 1 Apr 2002-31 Mar 2003

Corporate Author:

CASE WESTERN RESERVE UNIV CLEVELAND OH

Personal Author(s):

Report Date:

2003-04-01

Pagination or Media Count:

7.0

Abstract:

Most research that requires the long-term propagation of prostate cancer PCA cells in culture is carried out with three cell lines DU 145, PC-3, and LNCaP. All of these lines were derived from metastases only one, LNCaP, makes prostate specific antigen PSA andor androgen receptor. Neither DU 145 nor PC-3 exhibit any phenotypic markers specific for prostatic epithelial cells. Better models are needed. There is evidence that some prostatic fluids contain PCA cells. For this proposal, our goals are 1 to test the tumorigenicity of and to develop transplantable xenografts from PCA cells in prostatic fluid, 2 to develop methods for enhancing the tumorigenicity of small numbers of these PCA cells without deliberately altering their genes, 3 to test these methods for enhancement of tumorigenicity with prostatic fluid cells, and 4 to initiate clinical follow-up. To date, we have detected significant, often sustained elevations of PSA in the blood of several mice that received prostatic fluid cells for many months after injection. In the case of two mice that received prostatic fluid cells from one patient, PSA increased progressively over the course of a year but started to fall at the 12-month time point. Cells from the injections sites were transplanted one recipient has an elevated PSA. We have studied the coinjection of lethally irradiated, growth-factor- producing cells from several tumors with encouraging results in the case of some tumors.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE